Abstract: The present invention relates to a transgenic non-human animal embryo lacking native presenilin 1 and a transgenic non-human animal having only a non-native presenilin 1. The transgenic animals and cells derived therefrom can be used in the study of the expression pattern, activity and modulators of presenilin 1, in the study of the role of presenilin 1 in Alzheimer's Disease and in the study of disorders of the central nervous system.

Abstract: A substituted triazolopyridazine derivative, its use in cognition enhancement therapy, compositions containing it and processes for its manufacture.

Abstract: To provide an ultraviolet absorbent having high UV shieldability, especially UV-A shieldability, high transparency and good dispersibility. An ultraviolet absorbent, which comprises a flaky substrate coated with ultra-fin zinc oxide particles having a mean particle size of not larger than 100 nm, and which is optionally treated with an organic silicone compound; and a method for producing the ultraviolet absorbent, which comprises calcining particles as coated with basic zinc carbonate in the presence of a complex-forming agent.

Abstract: A PDE4 inhibiting compound is represented by

Abstract: The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein X is CH2, O or S. The compounds inhibit gamma secretase without affecting Notch signalling, and hence find use in the treatment or prevention of Alzheimer's disease.

Abstract: The invention relates to a method for disubstituting carboxylic acid amides on the geminal carbonyl-C-atom using at least one grignard reagent in the presence of a metal alcoholate compound used as a catalyst and in the presence of another organometallic compound used as a co-catalyst.

Abstract: The invention encompasses the novel class of compounds represented by formula I, which are inhibitors of the PTP-1B enzyme. The invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

Abstract: The present invention relates to fluoro-&agr;,&ohgr;-bis[(fluoroalkyl)fluorophosphorano)]alkanes, to a process for their preparation, and to their use as intermediates.

Abstract: Fluoroalkylphosphate salts of Formula I, described herein, are suitable for use, alone or in mixtures with, e.g., other salts, in electrolytes, primary batteries, secondary batteries, capacitors, supercapacitors or galvanic cells.

Abstract: Compounds represented by formula I: as well as pharmaceutically acceptable salts, esters, N-oxides and hydrates thereof are disclosed. Pharmaceutical compositions and methods of use are also included. The compounds are active against the caspase-3 enzyme, and thus are useful to treat fin caspase-3 mediated diseases and conditions.

Abstract: A compound of formula I, or a salt or prodrug thereof: wherein: Z represents C1-6 alkyl, C3-7 cycloalkyl, C4-7 cycloalkenyl, aryl, C3-7 heterocycloalkyl, heteroaryl or di(C1-6)alkylamino, any of which groups may be optionally substituted; R1 represents an optionally substituted five-membered heteroaromatic ring selected from oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; or R1 represents an optionally substituted six-membered heteroaromatic ring selected from pyrazine, pyrimidine and pyridazine; and R2 represents cyano(C1-6)alkyl, hydroxy(C1-6)alkyl, C3-7 cycloalkyl(C1-6)alkyl, propargyl, C3-7 heterocycloalkylcarbonyl(C1-6)alkyl, aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted; its use in treating anxiety and pharmaceutical compositions comprising it; a subclass of compounds which are useful in enhancing cognition, such as Alzheimer's Disease, is also disclosed.

Abstract: The present invention relates to 2,6-di-tert-butylphenols of the formula I in which R, A1 A2, Z1, Z2 m and n are as defined herein, and their use as stabilizers or antioxidants.

Abstract: Amine salts of 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid are potent antagonists of the integrin &agr;v&bgr;3 receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts. Also disclosed are 3(R)- and 3(S)-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-nonanoic acid in the form of a zwitterion trihydrate.

Abstract: Acetylene derivatives of the formula I in which R, A1, A2, Z1, Z2, Z3, L1, L2, L3, Y, m and n are as defined herein are suitable as components of liquid-crystalline media.

Abstract: The invention relates to a plastic part having lustrous pigments and filler particles. Moldings of this plastic part exhibit a pronounced glitter effect.

Abstract: Described are dialkyne compounds of the formula I 1

Abstract: Liquid-crystalline media comprising one or more compounds of formula A 1

Abstract: The invention relates to a method of preparing lithium complex salts and their intermediaries and to the use of these in electrolytes.

Abstract: Polymorphic, amorphous and hydrated forms of the title compound having the following structure: are disclosed. The compound is a potent and selective cyclooxygenase-2 (COX-2) inhibitor.

Abstract: The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemothera-peutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.